40 completed, 7 unknown, 6 terminated, 5 not yet recruiting. 19 Phase 4, 18 Not applicable, 16 Phase 2, 4 Phase 3, 2 Phase 1.
Follow Orlistat: new trials by email Literature Review of Orlistat trials Research Report on Orlistat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Orlistat Plus Progestin for Fertility-Sparing Treatment of Endometrial Cancer or Atypical Hyperplasia Orlistat, Progestin - Endometrial Neoplasms, Endometrial Cancer | Phase 2 | Not yet recruiting | Peking University People's Hospital | 48 | 2026-07-01 | 2026-07-20 |
| RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients. liraglutide monotherapy, liraglutide combined with orlistat - Overweight and Obese Adults | Phase 4 | Not yet recruiting | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | 120 | 2026-05-01 | 2026-03-23 |
| Effect of Electroacupuncture on Central Obesity and Fatty Liver in Postmenopausal Women Medical treatment, Hypocaloric diet, Electroacupuncture - Postmenopausal Women | Not applicable | Completed | Cairo University | 60 | 2026-03-01 | 2026-10-14 |
| Effect of Orlistat on Metabolic and Hormonal Features in Women With Polycystic Ovary Syndrome (PCOS): a Randomized Controlled Clinical Trial Orlistat, Placebo, Standard Lifestyle Advice - Polycystic Ovary Syndrome | Not applicable | Recruiting | Khyber Medical University Peshawar | 120 | 2026-01-01 | 2026-08-05 |
| Orlistat and Weight Management for Uric Acid Control in Obese Gout: A RCT Orlistat 120 mg, Allopurinol 100 up to 600mg/day, Febuxostat 40mg Tab - Gout, Obesity | Not applicable | Not yet recruiting | XueMei Guo | 120 | 2025-12-10 | 2026-01-08 |
| A Trial With EMP16 in Preparation for Late Phase Studies EMP16-02 120 mg orlistat/40 mg acarbose, Alli® 60 mg, Vi-Siblin® S - Overweight or Obese, Obesity and Overweight | Phase 2 | Not yet recruiting | Empros Pharma AB | 39 | 2025-05-20 | 2025-05-28 |
| Orlistat Overcoming Third-generation EGFR-TKI Resistance Orlistat 120 mg - Lung Adenocarcinoma, Osimertinib | Phase 2 | Not yet recruiting | Ping Peng | 36 | 2025-02-16 | 2025-02-12 |
| Long Term Efficacy and Safety of Orlistat for Type 1 Hyperlipoproteinemia Orlistat, Placebo - Type 1 Hyperlipoprotenemia | Phase 2 | Recruiting | University of Texas Southwestern Medical Center | 28 | 2024-01-26 | 2026-07-21 |
| Anti-obesity Effects of Dandelion (Taraxacum Officinale L.) Xenical, The dandelion extract - Obese Women, Perimenopause | Not applicable | Completed | October 6 University | 120 | 2024-01-05 | 2024-10-03 |
| Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease Liraglutide, Orlistat - Non-alcoholic Fatty Liver Disease, Obesity | Phase 4 | Unknown | Affiliated Hospital of Nantong University | 102 | 2023-11-01 | 2024-07-15 |
| Study Exploring the Supportive Effect of Acarbose in Weight Management EMP16-120/40, MR orlistat 120 mg, Conventional orlistat 120 mg, - Overweight or Obesity | Phase 2 | Unknown | Empros Pharma AB | 320 | 2023-04-18 | 2024-02-20 |
| A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America Semaglutide, Orlistat, Phentermine/Topiramate - Obesity | Phase 4 | Completed | Novo Nordisk A/S | 500 | 2023-01-19 | 2026-01-14 |
| Orlistat Reduces Uric Acid in Overweight/Obese Patients With Hyperuricemia Orlistat, Orlistat placebo - Uric Acid | Phase 4 | Completed | Shanghai 10th People's Hospital | 72 | 2022-08-26 | 2023-12-14 |
| Pharmacodynamic Equivalence Study Of Orlistat Capsules 60 mg Orlistat 60mg Cap - Bioequivalence | Not applicable | Completed | Shandong New Time Pharmaceutical Co., LTD | 84 | 2020-10-01 | 2021-10-13 |
| EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial Weight Management Program (WMP), Traditional care, Phentermine / Topiramate Extended Release Oral Capsule - Type 2 Diabetes, Obesity | Phase 4 | Terminated | The Cleveland Clinic | 74 | 2020-09-01 | 2024-09-19 |
| Life Style Modification Medical and Surgical Management in Patients With Obesity bariatric surgey - Obesity, Weight Change, Body | Unknown | Marmara University | 1000 | 2020-01-01 | 2020-06-04 | |
| Ezetimibe and Orlistat Affect the Intestinal Flora of Hyperlipidemia. Ezetimibe 10mg, Orlistat 120 MG - Hyperlipidemia | Unknown | Fifth Affiliated Hospital of Xinjiang Medical University | 58 | 2019-04-01 | 2019-03-21 | |
| Orlistat/Phentermine Versus Placebo/Phentermine Orlistat 120Mg Cap, Phentermine Pill - Obesity, Overweight | Not applicable | Completed | Gangnam Severance Hospital | 114 | 2018-10-16 | 2019-11-04 |
| Weight Loss Aid in an Exposed Population Orlistat, Placebo capsule, Multivitamin - Polybrominated Biphenyl Poisoning | Phase 4 | Completed | Emory University | 100 | 2018-09-14 | 2026-10-20 |
| Research of Intensive Metabolic Intervention Before Pregnancy in PCOS Acarbose 100 MG, Exenatide, Orlistat - PCOS, Impaired Glucose Tolerance | Phase 4 | Unknown | RenJi Hospital | 160 | 2018-01-01 | 2017-12-26 |
Showing 20 of 62. Sign in to see all of them.
Obesity (33) · Overweight (13) · Weight Loss (6) · Diabetes Mellitus (5) · Diabetes Mellitus, Type 2 (4) · Bulimia (3) · Hypertension (3) · Metabolic Syndrome (3) · Polycystic Ovary Syndrome (3) · Dyslipidemias (2) · Fatty Liver (2) · Glucose Intolerance (2) · Hypertriglyceridemia (2) · Insulin Resistance (2) · Non-alcoholic Fatty Liver Disease (2)
GlaxoSmithKline (4) · University of Texas Southwestern Medical Center (3) · Yale University (3) · Empros Pharma AB (2) · Hoffmann-La Roche (2) · Novo Nordisk A/S (2) · Pennington Biomedical Research Center (2) · University of Campinas, Brazil (2) · Affiliated Hospital of Nantong University (1) · Albany College of Pharmacy and Health Sciences (1) · Alizyme (1) · Aristotle University Of Thessaloniki (1) · Brooke Army Medical Center (1) · Cairo University (1) · Certmedica International GmbH (1)
United States (25) · China (6) · Brazil (4) · Sweden (4) · Netherlands (3) · United Kingdom (3) · Denmark (2) · Egypt (2) · Finland (2) · South Korea (2) · Switzerland (2) · Belgium (1) · Canada (1) · Czechia (1) · Germany (1)
Abhimanyu Garg, MD (2) · Carlos M Grilo, PhD (2) · Abbas Aflatoonian, Professor (1) · Abhimanyu G Garg, MD (1) · Alberto Cukier, PhD (1) · Anita J Marsaioli, Dr (1) · Anja M. Hafkamp, MD (1) · Annamaria Colao, MD, PhD (1) · Anne Steiner, MD MPH (1) · Anton Cheng, MBBS (1) · Bartolome Burguera (1) · Brent A Tetri, MD (1) · Bruno Geloneze, Dr (1)
PMID 38468241, PMID 12105286, PMID 12126214, PMID 15112907, PMID 17053334, PMID 19053049, PMID 19212822, PMID 19461584, PMID 19853906, PMID 20101008, PMID 20101009, PMID 21502796, PMID 21844879, PMID 21962313, PMID 22140269, PMID 23061407, PMID 23376451, PMID 23911112, PMID 23942319, PMID 24262967, PMID 24411757, PMID 25280441, PMID 26210388, PMID 26401593, PMID 27172435, PMID 27253669, PMID 27707818, PMID 28097013, PMID 28163748, PMID 28386912, PMID 28473337, PMID 28950422, PMID 29659879, PMID 29718281, PMID 30085130, PMID 31870173, PMID 32968804, PMID 32985114, PMID 33059389, PMID 33059886, PMID 33399399, PMID 33688228, PMID 34582624, PMID 34907116, PMID 35041662, PMID 35342538, PMID 35513159, PMID 36388084, PMID 37719091, PMID 37993515
K23MH066330 (1), R01DK049587 (1), R01ES025775 (1)